GenBen Lifesciences Corporation – Trademark Portfolio
Entity Type: 03
GenBen Lifesciences Corporation holds 3 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 44 (Medical Services) — 3 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 2 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include GBINSIGHT and GB LONGEVITY100. The owner is based in San Diego, CA.
suite 100
6310 Greenwich Drive
San Diego, CA 92122
Showing of trademarks Trademarks
Trademark Classifications
GenBen Lifesciences Corporation's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does GenBen Lifesciences Corporation have?
GenBen Lifesciences Corporation has 3 U.S. trademarks filed with the USPTO. Of these, 2 registered, 1 abandoned.
What trademark classes does GenBen Lifesciences Corporation file in?
GenBen Lifesciences Corporation files trademarks across 2 Nice Classification classes. The most active classes are Class 44 (Medical Services), Class 42 (Computer & Scientific). Class 44 covers medical services; veterinary services; hygienic and beauty care for human beings or animals.
What are GenBen Lifesciences Corporation's most well-known trademarks?
GenBen Lifesciences Corporation's registered trademark portfolio includes well-known marks such as GBINSIGHT and GB LONGEVITY100. These are among 2 currently registered trademarks in the portfolio.
What is GenBen Lifesciences Corporation's trademark registration success rate?
GenBen Lifesciences Corporation has a 67% trademark registration rate, with 2 out of 3 resolved applications resulting in successful registration. Currently, 0 applications are pending review.